Virtus Health Sciences A (RAGHX)
30.25
+0.31 (+1.04%)
USD |
Jul 01 2022
Returns Chart
Key Stats
Customize
| Expense Ratio | Total Assets Under Management | Dividend Yield | Turnover Ratio |
|---|---|---|---|
| 1.36% | 180.12M | 0.00% | 102.0% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized All Time Total Returns (Daily) | Max Drawdown (All) |
| -6.685M | -3.64% | Upgrade | Upgrade |
Basic Info
| Investment Strategy | |
| The investment seeks long-term capital appreciation. The fund seeks to achieve its objective by normally investing at least 80% of its net assets (plus borrowings made for investment purposes) in health sciences-related companies. The portfolio manager considers health sciences-related companies to include companies that design, manufacture or sell products or services used for or in connection with healthcare, medicine or life sciences. The fund will invest primarily in common stocks and other equity securities. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | RAGHX |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | Virtus |
| Prospectus Benchmark Index | |
| MSCI World/Health Care NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Peter Pirsch | 4.20 yrs |
| Christopher Chin | 1.76 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
39
-6.685M
-3.341B
Category Low
9.417B
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of June 30, 2022
Performance Versus Category
As of July 01, 2022. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of July 01, 2022.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| AstraZeneca PLC ADR | 6.22% | 65.95 | -0.18% |
| Pfizer Inc | 6.00% | 52.31 | -0.23% |
| Eli Lilly and Co | 5.03% | 324.71 | 0.15% |
| Merck & Co Inc | 4.69% | 92.42 | 1.37% |
| AbbVie Inc | 4.36% | 153.80 | 0.42% |
| Bristol-Myers Squibb Co | 3.95% | 76.84 | -0.21% |
| Roche Holding AG ADR | 3.91% | 42.01 | 0.72% |
| CVS Health Corp | 3.49% | 93.94 | 1.38% |
| Amgen Inc | 3.11% | 245.55 | 0.92% |
| Thermo Fisher Scientific Inc | 3.09% | 548.27 | 0.92% |
Basic Info
| Investment Strategy | |
| The investment seeks long-term capital appreciation. The fund seeks to achieve its objective by normally investing at least 80% of its net assets (plus borrowings made for investment purposes) in health sciences-related companies. The portfolio manager considers health sciences-related companies to include companies that design, manufacture or sell products or services used for or in connection with healthcare, medicine or life sciences. The fund will invest primarily in common stocks and other equity securities. |
| General | |
| Security Type | Mutual Fund |
| Oldest Share Symbol | RAGHX |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Category Name | Health |
| Category Index | S&P 1500 Health Care TR |
| Prospectus Objective | Specialty - Health |
| Fund Owner Firm Name | Virtus |
| Prospectus Benchmark Index | |
| MSCI World/Health Care NR USD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
| Manager Tenure | |
| Peter Pirsch | 4.20 yrs |
| Christopher Chin | 1.76 yrs |
Fundamentals
| General | |
| Distribution Yield | Upgrade |
| Dividend Yield TTM (7-1-22) | 0.00% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield (1-29-21) | Upgrade |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | 20.99 |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of May 31, 2022
Growth Estimates
Fund Details
| Key Dates | |
| Inception Date | 2/5/2002 |
| Last Annual Report Date | 6/30/2021 |
| Last Prospectus Date | 10/28/2021 |
| Share Classes | |
| AAAEX | Other |
| HLHIX | Inst |
| RCGHX | C |
| Attributes | |
| Enhanced Index Fund | No |
| Index Fund | No |
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |